- Plus Therapeutics partners with SpectronRx to produce Rhenium (186Re) Obisbemeda for CNS cancer therapies.
- The partnership supports upcoming clinical trials and future commercial demand for radiotherapeutics.
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on central nervous system (CNS) cancers, has entered a Manufacturing Services Agreement (MSA) with SpectronRx, a radiopharmaceutical contract development and manufacturing organisation (CDMO). The partnership will enable the production of Rhenium (186Re) Obisbemeda, a radiotherapy targeted at treating CNS cancers, including leptomeningeal metastases and recurrent glioblastoma.
This strategic agreement will see SpectronRx utilise its advanced facilities to meet the production demands of late-stage clinical trials planned for 2025 and future commercial use. “We believe that SpectronRx’s capabilities will significantly reinforce our existing manufacturing partnerships and position us well for the long term,” said Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics.
SpectronRx, which operates over 170,000 square feet of rCDMO space across multiple locations and serves 29 countries, will leverage its infrastructure and expertise in nuclear medicine to support Plus Therapeutics’ objectives. SpectronRx President, Anwer Rizvi, commented, “This collaboration underscores our dedication to advancing nuclear medicine and providing patients with high-quality, life-saving radiotherapies.”
The partnership aims to establish robust supply chain redundancy for Plus Therapeutics, ensuring that the manufacturing needs for both late-stage clinical trials and potential commercial rollout are met efficiently. Through this alliance, Plus Therapeutics and SpectronRx are poised to expand the reach of Rhenium (186Re) Obisbemeda, a treatment with promise in addressing critical CNS cancer care gaps.
Read about the Radiopharmaceutical CDMO Market Here.
Overview of outsourcing trends 
